Biosergen FCF/Dettes

Que fait Biosergen ? Biosergen AB develops BSG005, a potentially disruptive antifungal drug demonstrating safety and potency advantages over competing antifungals. The company targets invasive fungal infections affecting immune-compromised AIDS, cancer, and transplant patients, aiming for a three-to-fourfold potency advantage at equal doses compared to current standard treatments. Biosergen AB conducts research and development through its subsidiary Biosergen AS, utilizing laboratory facilities in Trondheim, Norway, and other global locations. The firm focuses on addressing unmet medical needs in high-risk patient segments where existing antifungals cause kidney toxicity. Biosergen AB's primary product BSG005 is positioned for development in the biopharmaceutical sector, targeting healthcare providers and institutions treating immune-compromised patients. The company's research activities are carried out through Biosergen AS, focusing on innovative drug development to overcome limitations of current antifungal therapies. Biosergen AB's business model centers on advancing BSG005 through clinical development stages to secure regulatory approvals for commercialization. The company's revenue model relies on future commercialization of BSG005 after successful clinical trials and regulatory approvals. Biosergen AB does not currently generate revenue from product sales but is focused on research and development activities to progress BSG005 toward market entry. The firm's value proposition centers on providing a safer, more potent antifungal alternative that addresses critical safety concerns of existing treatments. Biosergen est l'une des entreprises les plus populaires sur Eulerpool.